EMD-24699
CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement)
EMD-24699
Single-particle3.8 Å
Deposition: 16/08/2021Map released: 24/08/2022
Last modified: 28/05/2025
Sample Organism:
Homo sapiens,
Severe acute respiratory syndrome coronavirus 2
Sample: CC6.30 Fab in complex with SARS-2-CoV-6P-Mut7 S protein
Fitted models: 7ru8
Deposition Authors: Ozorowski G, Turner HL, Ward AB
Sample: CC6.30 Fab in complex with SARS-2-CoV-6P-Mut7 S protein
Fitted models: 7ru8
Deposition Authors: Ozorowski G, Turner HL, Ward AB
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways.
Zhao F 
,
Keating C,
Ozorowski G,
Shaabani N,
Francino-Urdaniz IM,
Barman S,
Limbo O ,
Burns A,
Zhou P ,
Ricciardi MJ,
Woehl J ,
Tran Q,
Turner HL,
Peng L,
Huang D,
Nemazee D,
Andrabi R,
Sok D,
Teijaro JR,
Whitehead TA,
Ward AB,
Burton DR,
Jardine JG
(2022) iScience , 25 , 104914 - 104914
,
Keating C,
Ozorowski G,
Shaabani N,
Francino-Urdaniz IM,
Barman S,
Limbo O ,
Burns A,
Zhou P ,
Ricciardi MJ,
Woehl J ,
Tran Q,
Turner HL,
Peng L,
Huang D,
Nemazee D,
Andrabi R,
Sok D,
Teijaro JR,
Whitehead TA,
Ward AB,
Burton DR,
Jardine JG
(2022) iScience , 25 , 104914 - 104914
Grant Support:
- Bill & Melinda Gates Foundation: OPP1170236 (United States)
- Bill & Melinda Gates Foundation: INV-004923 (United States)